<DOC>
	<DOCNO>NCT02784704</DOCNO>
	<brief_summary>This Phase 3 , randomize , double-blind , double-dummy , multicenter , prospective study ass efficacy , safety , pharmacokinetics ( PK ) eravacycline compare meropenem treatment complicate intra-abdominal infection ( cIAIs ) .</brief_summary>
	<brief_title>Efficacy Safety Study Eravacycline Compared With Meropenem Complicated Intra-abdominal Infections</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Appendicitis</mesh_term>
	<mesh_term>Intraabdominal Infections</mesh_term>
	<mesh_term>Meropenem</mesh_term>
	<mesh_term>Thienamycins</mesh_term>
	<criteria>Male female participant hospitalize cIAI At least 18 year age Evidence systemic inflammatory response Abdominal pain flank pain ( without rebound tenderness ) , pain caused cIAI refer another anatomic area Able provide inform consent If male : must agree use effective barrier method contraception study 14 day follow last dose sexually active female childbearing potential If female , pregnant nursing , childbearing potential : either commit use least two medically accept , effective method birth control ( example , condom , oral contraceptive , indwell intrauterine device , hormonal implant /patch , injection , approve cervical ring ) study drug dose 14 day follow last study drug dose practice sexual abstinence Unlikely survive 68 week study period Creatinine clearance ≤50 milliliter ( mL ) /minute Presence possible sign significant hepatic disease Immunocompromised condition , include know human immunodeficiency virus ( HIV ) positivity , transplant recipient , hematological malignancy History moderate severe hypersensitivity reaction tetracycline , carbapenems , βlactam antibiotic , excipients contain study drug formulation Participation investigational drug device study within 30 day prior study entry Known suspect current central nervous system ( CNS ) disorder may predispose seizure low seizure threshold ( example , severe cerebral arteriosclerosis , epilepsy ) Antibioticrelated exclusion : 1 . Receipt effective antibacterial drug therapy cIAI continuous duration &gt; 24hours 72hours precede randomization [ however , participant document cIAI ( , know baseline pathogen ) receive least 72hours antibiotic therapy consider treatment failure may enrol . Treatment failure define persistent fever and/or clinical symptom ; development new intraabdominal abscess ≥72hours antibiotic therapy ] , 2 . Receipt meropenem carbapenem , tigecycline current infection , 3 . Need concomitant systemic antimicrobial agent effective cIAI study drug Refusal mechanical ventilation , dialysis hemofiltration , cardioversion , resuscitative measure drug/fluid therapy time consent Known suspect inflammatory bowel disease associate visceral abscess The anticipated need systemic antibiotic duration 14 day Systemic malignancy require chemotherapy , immunotherapy , radiation therapy , antineoplastic therapy within previous 3 month anticipate begin prior TestofCure ( TOC ) visit Known study entry cIAI cause pathogen ( ) resistant one study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>